WGS Canaccord analyst Kyle Mikson raised the firm's price target on GeneDx to $90 from $75 and keeps a Buy rating on the shares. The firm sa
WGS Canaccord analyst Kyle Mikson raised the firm's price target on GeneDx to $90 from $75 and keeps a Buy rating on the shares. The firm said its target increase is driven by higher long-term estimates in their 10-year DCF model, as well as a decrease in their discount rate assumption after a "de-risking" quarterly update.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.